Mutations de BRCA1/2: d'Angelina Jolie à la thérapie [BRCA mutations: from Angelina Jolie to specific therapies]

Détails

ID Serval
serval:BIB_0D4DB284C1A0
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Mutations de BRCA1/2: d'Angelina Jolie à la thérapie [BRCA mutations: from Angelina Jolie to specific therapies]
Périodique
Revue medicale suisse
Auteur⸱e⸱s
Lopez V.A., Stravodimou A., Unger S., Perey L., Zaman K.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
18/05/2016
Peer-reviewed
Oui
Volume
12
Numéro
519
Pages
973-974,976-977
Langue
français
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Résumé
While mutations in BRCA1 and BRCA2 are found in only a minority of breast cancer patients, their impact for those patients is important. It is a powerful risk factor for this disease with respectively 65% and 45% of the women developing breast cancer. It requires a specific screening program starting at age of 25 that includes magnetic resonance imaging and risk reduction measures such as bilateral mastectomy and oophorectomy can be proposed. The psychological impacts of the mutation and its implications are not negligible. The testimony of Angelina Jolie in 2013 certainly contributed to public awareness and helped the affected women to cope better with the situation. Cancer treatments are also influenced by detection of a mutation with an increased role for platinum derivatives and the recently developed specific therapies, such as PARP inhibitors.
Mots-clé
Antineoplastic Agents/administration & dosage, Antineoplastic Agents/pharmacology, BRCA1 Protein/genetics, BRCA2 Protein/genetics, Breast Neoplasms/genetics, Breast Neoplasms/prevention & control, Famous Persons, Female, Genetic Predisposition to Disease, Humans, Mass Screening/methods, Mastectomy/methods, Mutation, Ovariectomy/methods, Risk Reduction Behavior
Pubmed
Création de la notice
19/09/2021 15:23
Dernière modification de la notice
20/09/2021 5:41
Données d'usage